Everyone's IPF journey is unique, columnist Sam Kirton says, but that does not mean our experiences should become a competition.
An imbalance in gene activity in two types of immune cells explains why lung fibrosis after a severe COVID-19 infection doesn ...
Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.
Columnist Sam Kirton says that at his age, and as someone with pulmonary fibrosis, he's had much experience dealing with grief.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results